Evidence map›Paper›PMID 42327599›Full record

ArticleBlood neoplasia2026

Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial.

Adam J Olszewski, Abraham Avigdor, Sunil Babu, Itai Levi, Herbert Eradat, Uri Abadi, Houston Holmes, Matthew S McKinney, Dariusz Woszczyk, Krzysztof Giannopoulos and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Adam J OlszewskiDepartment of Medicine, Brown University, Providence, RI.
Abraham AvigdorDivision of Hematology and Bone Marrow Transplantation, Sheba Medical Center, Tel Hashomer, Tel Aviv, Israel.
Sunil BabuFort Wayne Medical Oncology and Hematology, Fort Wayne, IN.
Itai LeviSoroka University Medical Centre, Be'er-Sheva, Israel.
Herbert EradatDepartment of Medicine, University of California, Los Angeles, CA.
Uri AbadiFaculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Houston HolmesTexas Oncology/Baylor-Sammons Cancer Center, Dallas, TX.
Matthew S McKinneyDepartment of Medicine, Duke Cancer Institute, Durham, NC.
Dariusz WoszczykDepartment of Medicine, Institute of Medical Sciences, University of Opole, Opole, Poland.
Krzysztof GiannopoulosDepartment of Medicine, Medical University of Lublin, Lublin, Poland.
Wojciech JurczakMaria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland.
Jing JingGenentech, Inc, South San Francisco, CA.
Donghang LiRoche (China) Holding Ltd, Shanghai, China.
Habib HamidiGenentech, Inc, South San Francisco, CA.
Elicia PenuelGenentech, Inc, South San Francisco, CA.
Martin JanousekF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Michael C WeiGenentech, Inc, South San Francisco, CA.
Connie BatleviGenentech, Inc, South San Francisco, CA.
Wahib EadGenentech, Inc, South San Francisco, CA.
Gila SellamF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Netanel A HorowitzRambam Health Care Campus, Technion, Haifa, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42327599
PMCPMC13276744

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.